In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformans.
Fluvastatin, a cholesterol-lowering drug, exhibited minimal activity (MICs of 64 to >128 microg/ml) against Candida species and Cryptococcus neoformans. When fluvastatin was combined with fluconazole or itraconazole, both synergistic and additive effects were noted (fractional inhibitory concentration indices of < or = 0.156 to 0.625; fractional lethal concentration indices of < or = 0.156 to 0.75). This combined fungicidal activity was confirmed by time-versus-killing studies.
Chin
N X
NX
Mycology Resource Center, Columbia-Presbyterian Medical Center, New York, New York 10032, USA.
Weitzman
I
I
Della-Latta
P
P
D000924:Anticholesteremic Agents / Q000494:pharmacology*; D000935:Antifungal Agents / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects*; D003455:Cryptococcus neoformans / Q000187:drug effects*; D004357:Drug Synergism; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology*; D015725:Fluconazole / Q000494:pharmacology*; D000077340:Fluvastatin; D007211:Indoles / Q000494:pharmacology*; D017964:Itraconazole / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D013997:Time Factors
D000924:Anticholesteremic Agents; D000935:Antifungal Agents; D005229:Fatty Acids, Monounsaturated; D007211:Indoles; D017964:Itraconazole; D000077340:Fluvastatin; D015725:Fluconazole